Evidence map›Paper›PMID 36089846›Full record

ArticleIndian pediatrics2022

Conception of National Biologics Registry for Pediatric Rheumatology: Need of the Hour and the Way Forward.

Narendra Kumar Bagri, Sathish Kumar, Athimalaipet V Ramanan

Abstract read
PubMed Full text at PMC
In one paragraph

Article in Indian pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Narendra Kumar BagriDivision of Pediatric Rheumatology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India. Correspondence to: Dr Narendra Kumar Bagri, Division of Pediatric Rheumatology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi. drnarendrabagri@yahoo.co.in.
Sathish KumarPediatric Rheumatology, Department of Pediatrics, Christian Medical College, Vellore, Tamil Nadu, India.
Athimalaipet V RamananPaediatric Rheumatology, Bristol Royal Hospital for Children and Translational Health Sciences, University of Bristol, Upper Maudlin Street, Bristol, BS2 8BJ, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The outcome for children with rheumatic diseases has been dramatically altered by the use of biological therapies. Increasing use of these agents will need careful monitoring for long term safety, particularly in children. Current data on safety of these drugs stem exclusively from Western literature. There is clear need for a registry of all children with rheumatic diseases who are commenced on biological agents to ensure appropriate pharmacovigilance. In this perspective, we discuss the need for and the role of a biologics registry for children with rheumatic diseases in India.

Indexed as

Biological ProductsRheumatic DiseasesRheumatologyBiological FactorsChildHumansRegistriesBiological FactorsBiological Products

Identifiers

PMID36089846
PMCPMC9798937

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.